Application Note

Process-Economy Simulation Of mAb Capture Step With Protein A Chromatography Resin

Pharmaceutical Manufacturing

The choice of chromatography resin is ultimately driven by process-economy, of which key influencing factors often include process time, buffer consumption, resin lifetime, hardware requirements, labor, and facility footprint, to name a few. MabSelect PrismA is a next‑generation protein A resin with substantially improved performance compared with its predecessors. A significantly enhanced alkaline‑stability offers the possibility of cleaning the resin with high concentrations of low‑cost sodium hydroxide, to ensure a better process-economy while meeting the requirements of a stringent bioburden control. With enhanced properties of both the agarose base matrix and the protein A ligand, MabSelect PrismA also offers a notedly increased capacity compared with its predecessor resins. The improved capacity allows handling of the ever‑increasing upstream titers, resolving bottlenecks in downstream mAb processing.

This process-economy simulation demonstrates the influence of dynamic binding capacity (DBC) and alkaline-stability of the resin in the design of a process, focusing on factors directly related to resin volume requirements. The predecessor resins—MabSelect SuRe and MabSelect SuRe LX resins—were included for reference.

VIEW THE APPLICATION NOTE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: